Open Access
Subscription Access
Advances in Drug Therapies for Fallopian Tube Cancer
Abstract
Fallopian tube cancer is a rare but serious gynecological malignancy that frequently poses challenges regarding diagnosis and treatment. Platinum_ based chemotherapy is the standard first _ line treatment for Fallopian tube cancer partipates along with a union of drugs such as cisplatin as well as paclitaxel. These agents perform by interfering with the DNA od rapidly dividing cancer cells, stopping their growth and causing cell death. Poly ( ADP _ ribose) polymerase ( parp) inhibitors represent a important advance regarding the treatment of Fallopian tube cancer, particularly for patients with specific gene mutations such as BRCA 1 or BRCA 2. PARP inhibitors namely olaparib and niraparib, target the DNA repair process particularly in cancer cells, resulting in their demise. Immuno therapy has attracted lot if attention regarding cancer treatment across various types, along with Fallopian tube cancer. Bevacizumab is an anti ,_ angoogenic drug approved for use along with chemotherapy for treatment of Fallopian tube cancer. It performs by stopping VEGF. A protective participated in angiogenesis, thereby limiting the blood supply to tumors and impeding their growth. Finally it is concluded that an advancements in drug therapies gor Fallopian tube cancer have opened new avenues for personalized and targeted treatments.
References
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-13-S2-16. [PubMed]
Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA., Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 05;354(1):34-43. [PubMed]
Nardi M, Aloe A, De Marco S, Cognetti F, Iacovelli A, Atlante G, Calabresi F. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol. 1997 Jun;20(3):230-2. [PubMed]
Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol. 1997 Jan;64(1):109-13. [PubMed]
Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010 Jun 20;28(18):2958-65. [PubMed]
Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-87-S17-90. [PubMed]
Johnson DH, Paul D, Hande KR. Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Semin Oncol. 1997 Feb;24(1 Suppl 3):S22-5. [PubMed]
Panagos GE. Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. Semin Oncol. 1997 Feb;24(1 Suppl 3):S17-21. [PubMed]
Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007 Feb;18(2):317-23. [PubMed]
Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, Louie S, Gustafson NF, Brown MA, Orcutt C, Winograd B, Scadden DT. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999 Jun;17(6):1876-83. [PubMed]
Refbacks
- There are currently no refbacks.